Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomustine SCHEMBL3995 | 1.00 | ADRA2A (1.00) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL28262197 | 0.97 | ADRA2A (0.94) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL28159683 | 0.95 | ADRA2A (0.91) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL28123007 | 0.95 | ADRA2A (0.91) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL1831239 | 0.93 | ADRA2A (0.86) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Semustine SCHEMBL2350016 | 0.91 | ALDH1A1 (0.92) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL863570 | 0.91 | ADRA2A (0.83) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| SCHEMBL4634654 | 0.88 | ADRA2A (0.79) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| SCHEMBL3341311 | 0.87 | ADRA2A (0.77) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| SCHEMBL3341308 | 0.87 | ADRA2A (0.77) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| EP-4010072-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW Bio, LLC (US) | 2022-06-15 | — | — | EP | claimed |
| CN-114206435-A | Treatment of central nervous system disorders | 诺欧生物有限责任公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2021026218-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW BIO, LLC (US) | 2021-02-11 | — | — | WO | claimed |
| WO-2020222161-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2020-11-05 | — | — | WO | claimed |
| US-20180298109-A1 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS | COMPUGEN LTD (IL) | 2018-10-18 | — | — | US | claimed |
| US-20170037141-A1 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS | COMPUGEN LTD. (IL) | 2017-02-09 | — | — | US | claimed |
| US-20160244457-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | UNIV KANSAS (US) | 2016-08-25 | — | — | US | claimed |
| US-20150197526-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | UNIVERSITY OF KANSAS | 2015-07-16 | — | — | US | claimed |
| WO-2012058269-A2 | METHODS OF TREATING CANCER AND OTHER DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-05-03 | — | — | WO | claimed |
| US-20090208493-A1 | Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors | STC. UNM (US) | 2009-08-20 | — | — | US | claimed |
| WO-2009070331-A2 | COMPOUNDS AND METHODS FOR THE SELECTIVE INHIBITION OF ABCB1, ABCC1 AND ABCG2 TRANSPORTERS AND THE TREATMENT OF CANCERS, ESPECIALLY DRUG RESISTANT CANCERS AND HIGH THROUGHPUT FLOW CYTOMETRY ASSAY TO DETECT SELECTIVE INHIBITORS | STC.UNM (US) | 2009-06-04 | — | — | WO | claimed |
| US-20070185069-A1 | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents | ENTREMED, INC. | 2007-08-09 | — | — | US | claimed |
| WO-2007059111-A2 | ANTI-ANGIOGENIC ACTIVITY OF 2-METHOXYESTRADIOL IN COMBINATION WITH ANTI-CANCER AGENTS | ENTREMED, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| CN-118317947-A | Sortilin inhibitors | 索蒂纳制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11964021-B2 | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors | ENGENELC MOLECULAR DELIVERY PTY LTD (AU) | 2024-04-23 | — | — | US | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| EP-0739419-B1 | METHODS OF ASSAYING DNA-REPAIRING ENZYMES AND THEIR ALKYLATED DERIVATIVES | INST OF MOLECUL & CELL BIOLOGY (SG) | 1999-04-07 | — | — | EP | disclosed |
| EP-0739419-A1 | METHODS OF ASSAYING DNA-REPAIRING ENZYMES AND THEIR ALKYLATED DERIVATIVES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995019445-A1 | METHODS OF ASSAYING DNA-REPAIRING ENZYMES AND THEIR ALKYLATED DERIVATIVES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1995-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197526-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | ABCB1, ABCG2, ABCC5 | ADRA2A 1394/4885PDE4A 2323/4885ADRA1A 1011/4885 |
| US-20070185069-A1 | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents | VEGFA, PGF, MKI67 | ADRA2A 792/4885PDE4A 1360/4885ADRA1A 914/4885 |
| US-20160244457-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | ABCB1, ABCG2, ABCC5 | ADRA2A 1394/4885PDE4A 2323/4885ADRA1A 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.